Status:

TERMINATED

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Lead Sponsor:

AMAG Pharmaceuticals, Inc.

Conditions:

Iron Deficiency Anemia

Eligibility:

All Genders

6-17 years

Phase:

PHASE3

Brief Summary

Study evaluating the efficacy and safety of intravenous (IV) ferumoxytol compared with oral iron for the treatment of pediatric participants with chronic kidney disease (CKD).

Detailed Description

Study AMAG-FER-CKD-251 was a study evaluating the efficacy and safety of IV ferumoxytol in pediatric participants with dialysis-dependent CKD. Study AMAG-FER-CKD-252 (NCT01155388) was a study evaluati...

Eligibility Criteria

Inclusion

  • Key Inclusion Criteria for the combined AMAG-FER-CKD-251 and AMAG-FER-CDK-252 studies include:
  • Males or females 6 months to \<18 years of age
  • CKD non-dialysis participants or dialysis-dependent participants who were on peritoneal dialysis or stable hemodialysis prior to Screening
  • Had iron deficiency anemia defined as: a) hemoglobin level ≤12.0 grams/deciliter (g/dL) and b) with either transferrin saturation level ≤40% or ferritin level \<100 nanograms/milliliter (ng/mL)
  • Female participants of childbearing potential who were sexually active must have been on an effective method of birth control for at least 1 month prior to Screening and agreed to remain on birth control until completion of participation in the study
  • Key Exclusion Criteria for the combined AMAG-FER-CKD-251 and AMAG-FER-CDK-252 studies include:
  • History of allergy to either oral or IV iron
  • Hemoglobin level ≤7.0 g/dL
  • Serum ferritin level \>600 ng/mL
  • Female participants who were pregnant or intended to become pregnant, or were breastfeeding, were within 3 months postpartum, or had a positive serum pregnancy test

Exclusion

    Key Trial Info

    Start Date :

    October 17 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 24 2014

    Estimated Enrollment :

    14 Patients enrolled

    Trial Details

    Trial ID

    NCT01155375

    Start Date

    October 17 2011

    End Date

    June 24 2014

    Last Update

    April 4 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    AMAG Pharmaceuticals, Inc.

    Waltham, Massachusetts, United States, 02451